## Vafseo (vadadustat) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

## MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:		

		/
MEDICATIO		
WEDIGATIO	DISPENSING INFORI	VATUN

MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY	RENEWAL IF F	ENEWAL: DATE THERAPY	INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):				
Continued on next name				

Continued on next page

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management - Commercial Clients. Revision Date: 5.1.2025 **CAT009** 



## Vafseo (vadadustat) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? VES (if yes, complete below) NO					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
	ICD-10 Code(s):				
TO SUPPORT A PRIOR AUTHORIZ					
Will the patient be using the drug	as a part of the clinical trial?	es 🗌 No			
	dialysis for at least three months?				
Is the medication being prescribe	d by, or in consultation with, a nep	ohrologist? 🗌 Yes 🔲 No			
Does the patient have a pre-treatment hemoglobin level of 8 to 11 g/dl?					
Does the patient have adequate iron sotres as indicated by serum ferritin level of at least 100 mcg/L or serum transferrin saturation of at least 20%?  Ves  No (documentation required)					
Has the patient failed treatment with Retacrit? 🗌 Yes 🗌 No (documentation required)					
If no to the above, does the patient have a absolute contraindication to Retacrit?					
Renewal:					
Has the patient been undergoing dialysis for at least three months? 🗌 Yes 🗌 No					
Is the medication being prescribed by, or in consultation with, a nephrologist? 🗌 Yes 🗌 No					
Does the patient continue to have a hemoglobin level of less than 12 g/dl? 🗌 Yes 🗌 No					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					



## Vafseo (vadadustat) **Prior Authorization Request Form Caterpillar Prescription Drug Benefit**

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: \_\_\_\_\_ Date: \_\_\_\_\_ Date: \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

> FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

